Delving into the Latest Updates on Aperta Biosciences LLC with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

关联

1

项与 Aperta Biosciences LLC 相关的药物

APT-001

靶点-

作用机制-

在研机构

Aperta Biosciences LLC

原研机构

Aperta Biosciences LLC

在研适应症

睑缘炎

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

1

项与 Aperta Biosciences LLC 相关的临床试验

NCT06720896

/ Not yet recruiting临床2期

Vision and Inflammation Study Testing Anti-acarid Therapeutics (VISTA-1): A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.

The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to its vehicle control, and to establish that the therapeutic is safe and generally well tolerated by patients.

开始日期2025-05-01

申办/合作机构

Aperta Biosciences LLC

100 项与 Aperta Biosciences LLC 相关的临床结果

登录后查看更多信息

0 项与 Aperta Biosciences LLC 相关的专利（医药）

登录后查看更多信息

100 项与 Aperta Biosciences LLC 相关的药物交易

登录后查看更多信息

100 项与 Aperta Biosciences LLC 相关的转化医学

登录后查看更多信息